ELAB

PMGC Holdings Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001840563 Biotech & Drug Discovery

$2.61 −0.10 (−3.55%)

Oct 26 4:00 PM ET · prev $2.71

Market cap

$2.2M

Nano cap

Next earnings

Nov 12

in 16 days

1 year

−99.8%

from $1,428.00 · Oct 27

30 days

−45.4%

from $4.78

52-week range

$2.61–1,447.20

at the low

Avg volume 20D

32.0K

Sep 29 spike 201.5K

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 6 reports · 90 days

Balance 0 bearish · 0 bullish · 6 neutral oldest → newest, height = score

Avg score

·High conf. 4/6 ·Next Earnings date, Nov 12, 2026

Strongest NEUTRAL PMGC Holdings Inc. (ELAB) announced a binding payment agreement with Longevity Health Holdings to convert…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 23 PMGC Holdings subsidiary NorthStrive Defense Tech secured an exclusi…
R May 13 PMGC Holdings (ELAB) acquired 100% of A&B Aerospace, a precision CNC…
E Jul 1 FDA: NorthStrive Biosciences Announces Positive Results from Ph…
X Jul 31 Short interest falls 45.6% to 440.4K
X Aug 14 Short interest falls 39.6% to 265.9K
E Aug 20 Trading halt: Trading Halt: ELAB — T1 (News Pending)
X Aug 31 Short interest falls 90.4% to 25.4K
X Sep 15 Short interest jumps 35.2% to 34.4K

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsBULLISH

Q2 2026: 3 added (0 new), 0 trimmed or exited.
TrendDOWNTREND

41% below its 50-day average. New closing low $2.61 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
JANE STREET GROUP, LLC	DOUBLED	81,501	$98.6K
MORGAN STANLEY	DOUBLED	53,000	$64.1K
UBS Group AG	ADD	2,352	$2.8K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 12, 2026

Earnings date

ELAB Q3 2026 Earnings Scheduled — 2026-11-12

Recent

Sep 29, 2026

Contract

NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs

Sep 18, 2026

Contract

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health…

Aug 21, 2026

Press release

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration…

Aug 21, 2026

Trading halt

Halt Resumed: ELAB — trading resumed after T3 (News and Resumption Times)

Halted 2026-08-20T23:50:00.000Z | Resumed 2026-08-21T13:00:00.000Z

Aug 20, 2026

Trading halt

Trading Halt: ELAB — T3 (News and Resumption Times)

PMGC Holdings Inc. Common Stoc | Market: NASDAQ | Code: T3 — News and Resumption Times

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Jun 1, 2026	Braeden Lichti Director	AWARD	450,277 sh
Jun 1, 2026	Daley Juliana Director	AWARD	75,046 sh
Jun 1, 2026	Kovalyov George Director	AWARD	75,046 sh
Jun 1, 2026	Parry Jeffrey Director	AWARD	75,046 sh
Jun 1, 2026	Bensler Graydon Chief Executive Officer	AWARD	450,277 sh